(19)
(11) EP 2 635 681 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.10.2017 Bulletin 2017/40

(45) Mention of the grant of the patent:
23.08.2017 Bulletin 2017/34

(21) Application number: 11838938.6

(22) Date of filing: 07.11.2011
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
(86) International application number:
PCT/US2011/059588
(87) International publication number:
WO 2012/061810 (10.05.2012 Gazette 2012/19)

(54)

BASE MODIFIED OLIGONUCLEOTIDES

BASENMODIFIZIERTE OLIGONUKLEOTIDE

OLIGONUCLÉOTIDES À BASES MODIFIÉES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 05.11.2010 US 410672 P

(43) Date of publication of application:
11.09.2013 Bulletin 2013/37

(73) Proprietor: Miragen Therapeutics, Inc.
Boulder CO 80301 (US)

(72) Inventors:
  • VAGLE, Kurt
    Boulder Colorado 80301 (US)
  • DALBY, Christina
    Boulder Colorado 80301 (US)
  • MARSHALL, William S.
    Boulder Colorado 80301 (US)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56) References cited: : 
EP-A1- 1 860 115
US-A- 5 945 527
WO-A2-2009/012418
US-A1- 2009 137 506
   
  • THOMAS E. LEHMANN ET AL: "Triple-Helix Formation by Pyrimidine Oligonucleotides Containing Nonnatural Nucleosides with Extended Aromatic Nucleobases: Intercalation from the major groove as a method for recognizing C:G and T:A base pairs", HELVETICA CHIMICA ACTA, vol. 80, no. 6, 22 September 1997 (1997-09-22), pages 2002-2022, XP055156890, ISSN: 0018-019X, DOI: 10.1002/hlca.19970800618
  • ROOIJ VAN EVA ET AL: "Toward MicroRNA-Based Therapeutics for Heart Disease The Sense in Antisense", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 103, no. 9, 1 October 2008 (2008-10-01), pages 919-928, XP002629120, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.108.183426
  • JONATHAN D. VAUGHT ET AL: "Expanding the Chemistry of DNA for in Vitro Selection", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, no. 12, 31 March 2010 (2010-03-31), pages 4141-4151, XP055047152, ISSN: 0002-7863, DOI: 10.1021/ja908035g
  • B. H. YOO: "2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro", NUCLEIC ACIDS RESEARCH, vol. 32, no. 6, 26 March 2004 (2004-03-26) , pages 2008-2016, XP055156919, DOI: 10.1093/nar/gkh516
  • VAUGHT ET AL.: 'Expanding the chemistry of DNA for in vitro selection' J AM CHEM SOC. vol. 132, no. 12, 31 March 2010, pages 4141 - 4151, XP055047152
  • GOLD ET AL.: 'Aptamer-based multiplexed proteomic technology for biomarker discovery.' NATURE PRECEDINGS, [Online] 14 June 2010, pages 1 - 31 + 22PP, XP055089415 Retrieved from the Internet: <URL:http://precedings.nature.com/documents /4538/version/1/files/npre20104538-1.pdf> [retrieved on 2012-01-28]
  • EL SAFADI ET AL.: '5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.' J MED CHEM. vol. 53, no. 4, 25 February 2010, pages 1534 - 1545, XP055079739
  • ONO ET AL.: 'Nucleosides and nucleotides. 127. A novel and convenient post-synthetic modification method for the synthesis of oligodeoxyribonucleotides carrying amino linkers at the 5-position of 2'-deoxyuridine' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 4, no. 2, 1994, pages 361 - 366, XP026679111
  • KOROLEVA ET AL.: 'Synthesis and applications of 2-aminopyrimidine derivatives as key intermediates in chemical synthesis of biomolecules.' RUSSIAN CHEMICAL REVIEWS vol. 79, no. 8, October 2010, pages 655 - 681, XP008168149
  • COTTEN ET AL.: '2'-O-methyl, 2'-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event.' NUCLEIC ACIDS RESEARCH vol. 19, no. 10, 1991, pages 2629 - 2635, XP002229545
  • T. Ito: "Synthesis, thermal stability and resistance to enzymatic hydrolysis of the oligonucleotides containing 5-(N-aminohexyl)carbamoyl-2'-O-methyluridi nes", Nucleic Acids Research, vol. 31, no. 10, 15 May 2003 (2003-05-15), pages 2514-2523, XP055218766, DOI: 10.1093/nar/gkg374
  • E. C. M. Juan ET AL: "Crystal structures of DNA:DNA and DNA:RNA duplexes containing 5-(N-aminohexyl)carbamoyl-modified uracils reveal the basis for properties as antigene and antisense molecules", Nucleic Acids Research, vol. 35, no. 6, 1 March 2007 (2007-03-01), pages 1969-1977, XP055219030, ISSN: 0305-1048, DOI: 10.1093/nar/gkl821
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).